PHARMORIS £1.4m seed round - evidence-led medicines workflow platform

PHARMORIS is preparing a £1.4m seed round to move from controlled demo proof toward pilot-ready commercial deployment.

PHARMORIS is staff-facing medicines workflow software for healthcare organisations. It helps teams turn medicines signals into governed ActionCases, evidence packs, human review, source traceability, approval/gate workflows, blocker tracking, stakeholder acknowledgement, value review and audit trails.

The product is not autonomous prescribing, not a prescribing engine and not a substitute for pharmacists, clinicians, finance, procurement or governance judgement.

The investment thesis is that medicines opportunities often stall between data, committee decision, provider execution, blocker resolution and value review. PHARMORIS is designed to become the governed operating layer between dashboards, EPR/pharmacy systems, medicines optimisation teams, finance, providers and assurance owners.

Seed funding will support product hardening, pilot readiness, clinical-safety and assurance work, buyer evidence generation, security/accessibility maturity, and controlled commercial pilots.

I’m looking to speak with investors, strategic partners, regulatory/standards experts, NHS innovation leaders and healthtech operators who understand evidence-led software commercialisation, NHS adoption, medicines optimisation, AI governance and regulated workflow infrastructure.